1st Quarter - Report

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC for BOEHRINGER INGELHEIM USA CORPORATION

Firm
Client
Income
—
Expenses
$869,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Agriculture AGR

Animal and Plant Health Inspection Service/Center for Veterinary Biologics; veterinary labeling issues; Proposed Cephlosporin Ban - Food and Drug Administration (FDA)

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Medicare, Medicaid and Medicaid Expansion in health reform 340B (Medicaid) pricing in Tax Extenders (H.R. 4213)

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4213 (112th)

Alcohol and Drug Abuse ALC

Prescription Drug Abuse; The Stop Oxy Abuse Act (H.R. 1316)

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1316 (112th)

Copyright/Patent/Trademark CPT

Patent Settlements; H.R. 1706 and S. 5369, Financial Services Appropriations Bill -- Senate; Patent Bill (S. 23/H.R. 1249 -- America Invests Act); False Marketing (H.R. 4954)

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —
PAUL ROMNESS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4954 (112th), H.R. 1706 (112th), S. 23 (112th), H.R. 1249 (112th), S. 5369 (112th)

Health Issues HCR

Health care reform; Patient Protection and Affordable Care Act implementation - pricing/rebates; importation; coverage; comparative effectiveness; Independent Patient Advisory Board; drug shortages; The Preserving Access to Life Saving Medicines Act (S. 296)

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —
PAUL ROMNESS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 296 (112th)

Pharmacy PHA

Reauthorization of the Prescription Drug User Fee Act; Drug Safety

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

340B (Medicaid) Expansion

LobbyistCovered position, as disclosed
AMY CHEVALIER EFANTIS —
PAUL ROMNESS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.